|
1
|
Eriksson H: Heart failure: A growing
public health problem. J Intern Med. 237:135–141. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dickstein K, Cohensolal A, Filippatos G,
McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, Van
Veldhuisen DJ, Atar D, Hoes AW, et al: ESC Guidelines for the
diagnosis and treatment of acute and chronic heart failure 2008:
The Task Force for the diagnosis and treatment of acute and chronic
heart failure 2008 of the European Society of Cardiology. Developed
in collaboration with the Heart Failure Association of the ESC
(HFA) and endorsed by the European Society of Intensive Care
Medicine (ESICM). Eur Heart J. 29:2388–2442. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Frey N and Olson EN: Cardiac hypertrophy:
The good, the bad and the ugly. Annu Rev Physiol. 65:452003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
English BA, Appalsamy M, Diedrich A,
Ruggiero AM, Lund D, Wright J, Keller NR, Louderback KM, Robertson
D and Blakely RD: Tachycardia, reduced vagal capacity and
age-dependent ventricular dysfunction arising from diminished
expression of the presynaptic choline transporter. Am J Physiol
Heart Circ Physiol. 299:H799–H810. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Singh MV and Anderson ME: Is CaMKII a link
between inflammation and hypertrophy in heart? J Mol Med.
89:537–543. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Molkentin JD and Dorn GW II: Cytoplasmic
signaling pathways that regulate cardiac hypertrophy. Annu Rev
Physiol. 63:391–426. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nicol RL, Frey N and Olson EN: From the
sarcomere to the nucleus: Role of genetics and signaling in
structural heart disease. Annu Rev Genomics Hum Genet. 1:179–223.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang K, Xu X, Nie L, Xiao T, Guan X, He T,
Yu Y, Liu L, Huang Y, Zhang J and Zhao J: Indoxyl sulfate induces
oxidative stress and hypertrophy in cardiomyocytes by inhibiting
the AMPK/UCP2 signaling pathway. Toxicol Lett. 234:110–119. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pimentel DR, Amin JK, Xiao L, Miller T,
Viereck J, Oliver-Krasinski J, Baliga R, Wang J, Siwik DA, Singh K,
et al: Reactive oxygen species mediate amplitude-dependent
hypertrophic and apoptotic responses to mechanical stretch in
cardiac myocytes. Circ Res. 89:453–460. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nakamura K, Fushimi K, Kouchi H, Mihara K,
Miyazaki M, Ohe T and Namba M: Inhibitory effects of antioxidants
on neonatal rat cardiac myocyte hypertrophy induced by tumor
necrosis factor-alpha and angiotensin II. Circulation. 98:794–799.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bendall JK, Cave AC, Heymes C, Gall N and
Shah AM: Pivotal role of a gp91(phox)-containing NADPH oxidase in
angiotensin II-induced cardiac hypertrophy in mice. Circulation.
105:293–296. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hingtgen SD, Tian X, Yang J, Dunlay SM,
Peek AS, Wu Y, Sharma RV, Engelhardt JF and Davisson RL:
Nox2-containing NADPH oxidase and Akt activation play a key role in
angiotensin II-induced cardiomyocyte hypertrophy. Physiol Genomics.
26:180–191. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nguyen T, Nioi P and Pickett CB: The
Nrf2-antioxidant response element signaling pathway and its
activation by oxidative stress. J Biol Chem. 284:13291–13295. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Soares MP and Ribeiro AM: Nrf2 as a master
regulator of tissue damage control and disease tolerance to
infection. Biochem Soc Trans. 43:663–668. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Psaty BM, Smith NL, Siscovick DS, Koepsell
TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH and Furberg CD:
Health outcomes associated with antihypertensive therapies used as
first-line agents. A systematic review and meta-analysis. JAMA.
277:739–745. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang L, Zhou GB, Liu P, Song JH, Liang Y,
Yan XJ, Xu F, Wang BS, Mao JH, Shen ZX, et al: Dissection of
mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as
an effective treatment for promyelocytic leukemia. Proc Natl Acad
Sci USA. 105:pp. 4826–4831. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang J, Wang Y and Guo ML: Identification
and mapping of a novel hydroxysafflor yellow A (HSYA) biosynthetic
gene in Carthamus tinctorius. Biochem Genet. 49:410–415. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Min J and Wei C: Hydroxysafflor yellow A
cardioprotection in ischemia-reperfusion (I/R) injury mainly via
Akt/hexokinase II independent of ERK/GSK-3β pathway. Biomed
Pharmacother. 87:419–426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nurzynska D, Meglio FD, Castaldo C,
Miraglia R, Romano V, Sacco AM, Barbato V, Granato G, Belviso I,
Bancone C, et al: Cardiac primitive cells in the adult human heart
are influenced by Angiotensin II in chronic heart failure. Ital J
Anat Embryol. 119:2014.
|
|
20
|
Liu SX, Zhang Y, Wang YF, Li XC, Xiang MX,
Bian C and Chen P: Upregulation of heme oxygenase-1 expression by
hydroxysafflor yellow A conferring protection from
anoxia/reoxygenation-induced apoptosis in H9c2 cardiomyocytes. Int
J Cardiol. 160:95–101. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sahni A, Wang N and Alexis JD: UAP56 is an
important regulator of protein synthesis and growth in
cardiomyocytes. Biochem Biophys Res Commun. 393:106–110. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Y, Jiao R, Ma ZG, Liu WEI, Wu QQ, Yang
Z, Li FF, Yuan Y, Bian ZY and Tang QZ: Sanguinarine inhibits
angiotensin II-induced apoptosis in H9c2 cardiac cells via
restoring reactive oxygen species-mediated decreases in the
mitochondrial membrane potential. Mol Med Rep. 12:3400–3408. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Prathapan A, Vineetha VP and Raghu KG:
Protective effect of Boerhaavia diffusa L. against mitochondrial
dysfunction in angiotensin II induced hypertrophy in H9c2
cardiomyoblast cells. PLoS One. 9:e962202014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kumar RR, Madhusudhanan N, Shanmugam G,
Hong J, Devarajan A, Palaniappan S, Zhang J, Halade GV,
Darley-Usmar VM, Hoidal JR, et al: Abrogation of Nrf2 impairs
antioxidant signaling and promotes atrial hypertrophy in response
to high-intensity exercise stress. J Transl Med. 14:862016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Meloni M, Caporali A, Graiani G, Lagrasta
C, Katare R, Van Linthout S, Spillmann F, Campesi I, Madeddu P,
Quaini F and Emanueli C: Nerve growth factor promotes cardiac
repair following myocardial infarction. Circ Res. 106:1275–1284.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Olivetti G, Quaini F, Sala R, Lagrasta C,
Corradi D, Bonacina E, Gambert SR, Cigola E and Anversa P: Acute
myocardial infarction in humans is associated with activation of
programmed myocyte cell death in the surviving portion of the
heart. J Mol Cell Cardiol. 28:2005–2016. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
McMullen JR and Jennings GL: Differences
between pathological and physiological cardiac hypertrophy: Novel
therapeutic strategies to treat heart failure. Clin Exp Pharmacol
Physiol. 34:255–262. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Neeland IJ, Drazner MH, Berry JD, Ayers
CR, de Filippi C, Seliger SL, Nambi V, McGuire DK, Omland T and de
Lemos JA: Biomarkers of chronic cardiac injury and hemodynamic
stress identify a malignant phenotype of left ventricular
hypertrophy in the general population. J Am Coll Cardiol.
61:187–195. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hayashi D, Kudoh S, Shiojima I, Zou Y,
Harada K, Shimoyama M, Imai Y, Monzen K, Yamazaki T, Yazaki Y, et
al: Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy
through mitogen-activated protein kinase phosphatase-1. Biochem
Biophys Res Commun. 322:310–319. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li J, Ichikawa T, Villacorta L, Janicki
JS, Brower GL, Yamamoto M and Cui T: Nrf2 protects against
maladaptive cardiac responses to hemodynamic stress. Arterioscler
Thromb Vasc Biol. 29:1843–1850. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sugden PH and Clerk A: Cellular mechanisms
of cardiac hypertrophy. J Mol Med. 76:725–746. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tanaka K, Honda M and Takabatake T: Redox
regulation of MAPK pathways and cardiac hypertrophy in adult rat
cardiac myocyte. J Am Coll Cardiol. 37:676–685. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Todorova I, Simeonova G, Kyuchukova D,
Dinev D and Gadjeva V: Reference values of oxidative stress
parameters (MDA, SOD, CAT) in dogs and cats. Comp Clin Path.
13:190–194. 2005. View Article : Google Scholar
|
|
34
|
Omidi A, Namazi F, Jabire S, Afsar M,
Honarmand M and Nazifi S: The effects of starvation and refeeding
on oxidative stress parameters (MDA, SOD, GPx), lipid profile,
thyroid hormones and thyroid histopathology in male wistar rats.
Int Arch Med. 9(238)2016.
|
|
35
|
Wu CC, Hsu MC, Hsieh CW, Lin JB, Lai PH
and Wung BS: Upregulation of heme oxygenase-1 by
Epigallocatechin-3-gallate via the phosphatidylinositol
3-kinase/Akt and ERK pathways. Life Sci. 78:2889–2897. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li P, Su L, Li X, Di W, Zhang X, Zhang C,
He T, Zhu X, Zhang Y and Li Y: Remote limb ischemic
postconditioning protects mouse brain against cerebral
ischemia/reperfusion injury via upregulating expression of Nrf2,
HO-1 and NQO-1 in mice. Int J Neurosci. September 17–2015.(Epub
ahead of print). View Article : Google Scholar :
|
|
37
|
Tomita M, Okuyama T, Katsuyama H, Hidaka
K, Otsuki T and Ishikawa T: Gene expression in rat lungs during
early response to paraquat-induced oxidative stress. Int J Mol Med.
17:37–44. 2006.PubMed/NCBI
|
|
38
|
Wang T, Fu FH, Han B, Li GS, Zhang LM and
Liu K: Hydroxysafflor yellow A reduces myocardial infarction size
after coronary artery ligation in rats. Pharm Biol. 47:458–462.
2009. View Article : Google Scholar
|
|
39
|
Wei G, Yin Y, Duan J, Guo C, Zhu Y, Wang
Y, Xi M and Wen A: Hydroxysafflor yellow A promotes
neovascularization and cardiac function recovery through
HO-1/VEGF-A/SDF-1α cascade. Biomed Pharmacother. 88:409–420. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu YN, Zhu JH, Xiang WU and Wang ZH:
Mitochondrial mechanism of cardioprotective effect of
hydroxysafflor yellow A against anoxia/reoxygenation injury in
rats. J Jiangsu Univ (Medicine Edition). 23:2013.
|
|
41
|
Chen L, Xiang Y, Kong L, Zhang X, Sun B,
Wei X and Liu H: Hydroxysafflor yellow A protects against cerebral
ischemia-reperfusion injury by anti-apoptotic effect through
PI3K/Akt/GSK3β pathway in rat. Neurochem Res. 38:2268–2275. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhou MX, Fu JH, Zhang Q and Wang JQ:
Effect of hydroxy safflower yellow A on myocardial apoptosis after
acute myocardial infarction in rats. Genet Mol Res. 14:3133–3141.
2015. View Article : Google Scholar : PubMed/NCBI
|
